Drug or intervention
Rifampin Clinical Trials
Studies that test Rifampin, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 111Mycobacterium; Xenopi, Lung Diseases
Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection
Treatment of Mycobacterium xenopi (MX) lung disease is not-well- tolerated and concerned a growing number of patients, especially with chronic pulmonary diseases or immunosuppression.
- Trial name
- AKAPI (NCT06585020)
- Testing
- Arikayce, standard treatment
- Where
- France
- Volunteers
- 190 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or…
- Trial name
- QUANTUM-TB (NCT07209761)
- Testing
- Bedaquiline, Quabodepistat, Pretomanid
- Where
- 42 sites in China, Georgia and 8 more
- Volunteers
- 532 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis (TB)
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
People living in high TB burden communities who undergo active case finding for TB may have chest X-ray changes suggestive of TB but their sputum test can be negative for the TB bacteria or they are unable to provide a sputum…
- Trial name
- RADIO-TB (NCT07163143)
- Testing
- Isoniazid (H), Rifampicin (R), Pyrazinamide (Z)
- Where
- 4 sites in Pakistan, South Africa and 1 more
- Volunteers
- 784 people
- Sponsor
- University College, London
Non-Puerperal Mastitis
Ablation Versus Non-ablation Strategies for Non-puerperal Mastitis: A Prospective Real-world Registry Study
The goal of this prospective registry cohort study is to evaluate the efficacy and quality-of-life impact of ablation therapy in patients with non-puerperal mastitis.
- Trial name
- NCT07894614
- Testing
- Ablation, Observation
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Song Hongping
Drug Resistant Tuberculosis
Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment
The goal of the BringBPaL2Me Trial, a multi-principal investigator, multi-site, cluster randomized, non-inferiority trial is to compare nurse-led RR-TB treatment in primary care clinics to standard of care physician-led RR-TB…
- Trial name
- NCT05671718
- Testing
- Nurse-Led Treatment in Primary Care
- Where
- 5 sites in South Africa
- Volunteers
- 2,944 people
- Sponsor
- Johns Hopkins University
Healthy Adult Participants
A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose trial of TBD11 in healthy adults. It includes a dedicated open-label cohort in which TBD11 will be administered as a single dose with either a strong…
- Trial name
- NCT07883226
- Testing
- TBD11 (300 mg), Itraconazole (200 mg), Rifampicin 600mg
- Where
- South Africa
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Brucellosis
Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated Brucellosis
Brucellosis is a common zoonotic infectious disease. The standard dual regimen of doxycycline combined with rifampicin is widely used for uncomplicated brucellosis.
- Trial name
- BRUCE-U (NCT07887126)
- Testing
- Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin
- Where
- 3 sites in China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital of Shihezi University
Infective Endocarditis
Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis
The primary objective of this study is to demonstrate that a rifampin-free regimen is non-inferior to the rifampin-containing regimen in terms of all-cause mortality in staphylococcal prosthetic valve endocarditis within 6 months…
- Trial name
- RIFREE (NCT07345325)
- Testing
- Rifampin-free regimen, Rifampin containing regimen
- Where
- 31 sites in France
- Volunteers
- 422 people
- Sponsor
- Nantes University Hospital
Brucellosis, Osteoarticular Brucellosis
All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis
Brucellosis is a globally distributed zoonosis with persistent clinical management challenges. The World Health Organization (WHO)-recommended doxycycline-rifampin (DOX-RIF) dual regimen may drive rifampin-associated…
- Trial name
- BRUCE-O (NCT07887152)
- Testing
- Doxycycline + Rifampicin + Ceftriaxone (intravenous therapy for 4 weeks), Triple oral regimen (Doxycycline + Rifampicin + Levofloxacin), Triple oral regimen (Doxycycline + Rifampicin + Moxifloxacin)
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital of Shihezi University
Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection
Hypertonic Saline for MAC
The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.
- Trial name
- NCT04921943
- Testing
- Hypertonic saline, Azithromycin, Ethambutol
- Where
- 3 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Oregon Health and Science University
Completed, with results posted
All 106Tuberculosis
Tuberculosis Treatment Shortening Trial
Tuberculosis (TB) is a serious infection that can affect the lungs and other parts of the body. The usual way to treat TB is to take 4 medicines by mouth every day for 2 months, then take 2 of the same medicines for 4 more…
- Trial name
- NCT00130247
- Testing
- Ethambutol, Isoniazid, Pyrazinamide
- Where
- 3 sites in Brazil, Philippines and 1 more
- Volunteers
- 394 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers
A Study of Soticlestat and Rifampin in Healthy Adults
The main aim of this study is to check how rifampin affects the way soticlestat is processed by the body. Participants will be required to stay at the study clinic for 18 consecutive days.
- Trial name
- NCT05098041
- Testing
- Soticlestat, Rifampin
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Takeda
Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once…
- Trial name
- NCT04044001
- Testing
- BTZ-043, Rifafour e-275®, Probe Drug Cocktail
- Where
- 2 sites in South Africa
- Volunteers
- 78 people
- Sponsor
- Michael Hoelscher
Tuberculosis
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
The Tuberculosis Trials Consortium (TBTC) Study 31 is a phase 3 trial evaluating rifapentine-containing regimens for treatment-shortening of drug-susceptible pulmonary tuberculosis.
- Trial name
- S31PK/PD (NCT02563327)
- Testing
- Rifapentine, Moxifloxacin, Rifampin
- Where
- 3 sites in United States, Uganda and 1 more
- Volunteers
- 2,516 people
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients…
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR, Tuberculosis
- Trial name
- NCT03338621
- Testing
- Pretomanid, Bedaquiline, Moxifloxacin
- Where
- 26 sites in Brazil, Georgia and 6 more
- Volunteers
- 455 people
- Sponsor
- Global Alliance for TB Drug Development